Clinical Characteristics And Outcome Of COVID-19 Infection In Patients With Chronic Respiratory Diseases.

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05054127
Collaborator
(none)
100
13

Study Details

Study Description

Brief Summary

  1. To identify the pattern of presentation of COVID-19 in patients with chronic respiratory diseases

  2. To asses the severity of COVID-19 in patients with chronic respiratory diseases

  3. To identify the outcome of COVID-19 in patients with chronic respiratory diseases

Condition or Disease Intervention/Treatment Phase
  • Other: foiiow up patients

Detailed Description

Genomes analysis reveal that SARS-CoV-2 presents unique features: optimal affinity for angiotensin converting enzyme 2 (ACE2) receptor and a polybasic cleavage site at the S1/S2 spike junction that determines infectivity and host range [3-4) Patients with SARS-CoV-2 infection may present symptoms ranging from mild to severe with a large portion of the population being asymptomatic carriers. The most common reported symptoms include fever (83%), cough (82%) and shortness of breath (31%) [5-6]. Patients suffering from chronic respiratory diseases (CRD) such as chronic respiratory failure, asthma, chronic obstructive pulmonary disease (COPD), interstitial lung diseases (ILD), pulmonary hypertension (PH), sarcoidosis or cystic fibrosis (CF), were immediately considered to be at risk of severe forms of COVID-19 [7]. Indeed, COVID-19 is responsible for various respiratory symptoms, from cough with dyspnea to acute respiratory distress syndrome (ARDS) in its most severe presentation [8-9]. In parallel, it has been shown that COVID-19 patients have an increased risk of venous thromboembolic disease [10]. There is concern that the respiratory complications of COVID-19 could be deleterious in patients with prior CRD. [11-12-13] During COVID-19 pandemic, studies mostly demonstrated that COPD was related with worse outcomes. There may be a few reasons why the course of COVID-19 in COPD patients has been worse. Firstly, COPD patients tend to be older and have more comorbidities which may increase COVID-19 severity [14]. Respiratory failure and hypoxemia, which are the most important causes of death in COVID-19 patients, are more common in COPD patients [15]. Although the exact mechanism of acute exacerbation of ILD is not fully understood, the current belief is that it can be caused by numerous triggers, including infection, or it can be idiopathic.(16) It is likely that respiratory infection with COVID-19 could trigger an exacerbation of underlying ILD and result in poor outcomes. There is similar concern regarding the possibility of exacerbation in patients with sarcoidosis, especially those with fibrotic manifestations.(17)

  1. To identify the pattern of presentation of COVID-19 in patients with chronic respiratory diseases

  2. To asses the severity of COVID-19 in patients with chronic respiratory diseases

  3. To identify the outcome of COVID-19 in patients with chronic respiratory diseases

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Clinical Characteristics And Outcome Of COVID-19 Infection In Patients With Chronic Respiratory Diseases.
Anticipated Study Start Date :
Apr 15, 2022
Anticipated Primary Completion Date :
Apr 15, 2022
Anticipated Study Completion Date :
May 15, 2023

Outcome Measures

Primary Outcome Measures

  1. relation between covid 19 and patients with chronic respiratory diseases [Baseline]

    pattern of presentation of COVID-19 in patients with chronic respiratory diseases 2-To asses the severity of COVID-19 in patients with chronic respiratory diseases 3-To identify the outcome of COVID-19 in patients with chronic respiratory diseases The pattern of presentation of COVID-19 in patients with chronic respiratory diseases The severity of COVID-19 in patients with chronic respiratory diseases The outcome of COVID-19 in patients with chronic respiratory diseases

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  1. patients with chronic respiratory diseases diagnosed with covid-19 infection by PCR

  2. Patients aged 18 years and above

Exclusion Criteria:
  1. Patient aged below 18 years old.

  2. Patients refuse to share in our study

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Madonna Youssef Roshdy Kelada, Madonna youssef roshdy kelada, Assiut University
ClinicalTrials.gov Identifier:
NCT05054127
Other Study ID Numbers:
  • COVID-19 and CRD
First Posted:
Sep 23, 2021
Last Update Posted:
Feb 24, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 24, 2022